The current study along with demonstrated success with administration of exogenous IAP pave the way for developing appropriate platforms for intestinal delivery of active IAP enzyme (withstanding the low gastric pH‐dependent inactivation/degradation) as a novel and simple/noninvasive strategy for attenuation of WD‐induced metabolic changes including glucose intolerance and diabetes. The gene discussed is ALPI; the disease is Glucose intolerance.